Market access webinar

Navigating the updated 2020 ICER value assessment framework

In this webinar, US subject matter experts will provide an overview of changes in the recent update to the ICER value assessment framework (VAF), released in January 2020.

Fill in your details to watch this webinar

We respect your privacy. Cookie policy.

We will discuss potential implications of the changes to the ICER VAF, share a real-world example of how the updated VAF is being used, and examine ways to proactively use this updated framework to drive access for your brand.

Discussion points

  • Understand the role of ICER in the evolving US healthcare landscape
  • Review changes in the 2020 ICER VAF update
  • Understand the implications and real-world use of the updated 2020 ICER VAF

Duration: 30 minutes. Available to watch on demand.

Ideal viewing: This on-demand webinar is essential viewing for all global, regional, and affiliate market access and HEOR teams involved in the development of managed entry agreements. Please share this with your colleagues.

Broadcast: 2020

Navigating the updated 2020 ICER value assessment framework

Previous webinars

Driving BioPharma Access in Europe: Insights for Markets Outside of EU5  

Read more >

Positioning for market access success in the evolving landscape of precision medicine

Read more >

Navigating the cell and gene therapy market access landscape

Read more >

Understanding the concept of early scientific advice and its purpose across HTA markets

Read more >

Increase your influence in early pipeline planning: why earlier value assessment of your assets through a payer lens makes a difference.

Read more >

How to demonstrate the value of vaccines in line with global NITAG and HTA requirements

Read more >

Market access for biotechnology

Read more >

How to build an optimized GVD to populate local HTA/payer templates

Read more >

Recommendations for driving your journey to digital excellence

Read more >

The PRMA Healthcheck®: the future of market access in Asia-Pacific

Read more >

PRMA Healthcheck® for assets in early stages of clinical development

Read more >

The evolution of the PRMA Healthcheck® for US payer archetypes

Read more >

Accelerate the time to patient access with the PRMA Navigator®

Read more >

EUnetHTA joint clinical assessments: where have we come from and where are we going?

Read more >

Future proofing for the 2020s market access trends

Read more >

Managed entry agreements: lessons from EU5

Read more >

CAR-T therapy: the future begins to take shape

Read more >

Indication-specific pricing: the obvious solution

Read more >

Payer perspectives on cell and gene therapies: opportunities and challenges

Read more >

Market access considerations for CAR-Ts: insights from ASH

Read more >

Patient-centricity: shaping value generation for HTA and market access

Read more >

Market access for PD-1 inhibitors: where are we now?

Read more >

Does 1+1 always equal 2? Valuing combinations

Read more >

Clarity or confusion: the role of value frameworks in oncology

Read more >